Moleculin Total Current Liabilities vs Retained Earnings Analysis

MBRX Stock  USD 2.31  0.27  10.47%   
Moleculin Biotech financial indicator trend analysis is infinitely more than just investigating Moleculin Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moleculin Biotech is a good investment. Please check the relationship between Moleculin Biotech Total Current Liabilities and its Retained Earnings accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Total Current Liabilities vs Retained Earnings

Total Current Liabilities vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moleculin Biotech Total Current Liabilities account and Retained Earnings. At this time, the significance of the direction appears to have pay attention.
The correlation between Moleculin Biotech's Total Current Liabilities and Retained Earnings is -0.89. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Moleculin Biotech, assuming nothing else is changed. The correlation between historical values of Moleculin Biotech's Total Current Liabilities and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Moleculin Biotech are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Current Liabilities i.e., Moleculin Biotech's Total Current Liabilities and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.89
Relationship DirectionNegative 
Relationship StrengthSignificant

Total Current Liabilities

Total Current Liabilities is an item on Moleculin Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Moleculin Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.
Most indicators from Moleculin Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.Selling General Administrative is likely to drop to about 6.9 M in 2024. Issuance Of Capital Stock is likely to drop to about 200.4 K in 2024
 2021 2022 2023 2024 (projected)
Depreciation And Amortization260K222K127K120.7K
Interest Income306K240K1.2M965.1K

Moleculin Biotech fundamental ratios Correlations

-0.510.650.730.990.80.74-0.98-0.750.720.980.750.070.980.83-0.290.290.920.56-0.740.98-0.790.550.330.71-0.87
-0.510.020.04-0.54-0.01-0.220.5-0.040.02-0.5-0.42-0.29-0.5-0.20.25-0.13-0.18-0.090.38-0.490.32-0.37-0.34-0.080.3
0.650.020.850.60.860.79-0.58-0.910.720.570.710.050.570.850.010.350.780.65-0.730.58-0.680.510.260.74-0.75
0.730.040.850.650.780.86-0.63-0.890.960.620.80.270.620.87-0.160.530.90.84-0.820.65-0.850.650.410.92-0.85
0.99-0.540.60.650.780.66-0.99-0.680.630.990.68-0.030.990.75-0.230.150.880.43-0.670.99-0.710.440.210.6-0.79
0.8-0.010.860.780.780.66-0.79-0.940.720.790.56-0.250.790.86-0.220.220.890.52-0.580.79-0.660.350.140.68-0.77
0.74-0.220.790.860.660.66-0.63-0.790.860.620.850.430.620.87-0.160.580.780.81-0.850.64-0.770.80.590.85-0.88
-0.980.5-0.58-0.63-0.99-0.79-0.630.69-0.6-1.0-0.590.07-1.0-0.750.25-0.17-0.88-0.430.58-1.00.7-0.42-0.21-0.60.8
-0.75-0.04-0.91-0.89-0.68-0.94-0.790.69-0.85-0.68-0.68-0.03-0.68-0.960.33-0.5-0.9-0.760.7-0.70.79-0.6-0.42-0.860.88
0.720.020.720.960.630.720.86-0.6-0.850.60.790.350.60.86-0.330.60.860.86-0.80.63-0.870.70.520.93-0.86
0.98-0.50.570.620.990.790.62-1.0-0.680.60.59-0.071.00.75-0.250.170.880.42-0.581.0-0.690.410.210.6-0.79
0.75-0.420.710.80.680.560.85-0.59-0.680.790.590.430.590.77-0.250.50.730.74-1.00.61-0.810.760.540.76-0.78
0.07-0.290.050.27-0.03-0.250.430.07-0.030.35-0.070.43-0.070.23-0.170.670.050.57-0.39-0.04-0.490.720.760.49-0.35
0.98-0.50.570.620.990.790.62-1.0-0.680.61.00.59-0.070.75-0.250.170.880.42-0.581.0-0.690.410.210.6-0.79
0.83-0.20.850.870.750.860.87-0.75-0.960.860.750.770.230.75-0.440.640.910.84-0.780.77-0.880.780.620.92-0.97
-0.290.250.01-0.16-0.23-0.22-0.160.250.33-0.33-0.25-0.25-0.17-0.25-0.44-0.64-0.3-0.490.24-0.270.45-0.53-0.67-0.40.45
0.29-0.130.350.530.150.220.58-0.17-0.50.60.170.50.670.170.64-0.640.420.91-0.510.2-0.670.890.920.75-0.66
0.92-0.180.780.90.880.890.78-0.88-0.90.860.880.730.050.880.91-0.30.420.72-0.750.89-0.840.590.360.85-0.92
0.56-0.090.650.840.430.520.81-0.43-0.760.860.420.740.570.420.84-0.490.910.72-0.750.46-0.860.90.80.94-0.85
-0.740.38-0.73-0.82-0.67-0.58-0.850.580.7-0.8-0.58-1.0-0.39-0.58-0.780.24-0.51-0.75-0.75-0.60.8-0.74-0.51-0.760.77
0.98-0.490.580.650.990.790.64-1.0-0.70.631.00.61-0.041.00.77-0.270.20.890.46-0.6-0.720.440.240.63-0.81
-0.790.32-0.68-0.85-0.71-0.66-0.770.70.79-0.87-0.69-0.81-0.49-0.69-0.880.45-0.67-0.84-0.860.8-0.72-0.8-0.67-0.940.92
0.55-0.370.510.650.440.350.8-0.42-0.60.70.410.760.720.410.78-0.530.890.590.9-0.740.44-0.80.940.84-0.83
0.33-0.340.260.410.210.140.59-0.21-0.420.520.210.540.760.210.62-0.670.920.360.8-0.510.24-0.670.940.7-0.67
0.71-0.080.740.920.60.680.85-0.6-0.860.930.60.760.490.60.92-0.40.750.850.94-0.760.63-0.940.840.7-0.94
-0.870.3-0.75-0.85-0.79-0.77-0.880.80.88-0.86-0.79-0.78-0.35-0.79-0.970.45-0.66-0.92-0.850.77-0.810.92-0.83-0.67-0.94
Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets25.2M29.0M84.1M57.4M38.2M35.4M
Other Current Liab164K1.7M2.2M2.6M4.2M4.4M
Total Current Liabilities3.6M2.9M3.6M4.8M6.8M3.7M
Total Stockholder Equity15.6M17.8M79.0M52.2M26.1M28.9M
Net Tangible Assets3.1M4.4M6.6M67.8M78.0M81.9M
Net Debt(10.4M)(14.9M)(70.7M)(42.7M)(23.0M)(24.1M)
Retained Earnings(39.6M)(56.9M)(72.8M)(101.8M)(131.6M)(125.0M)
Accounts Payable2.2M1.1M1.4M2.1M2.5M1.5M
Cash10.7M15.2M70.9M43.1M23.6M22.4M
Non Current Assets Total11.8M11.8M11.6M11.8M11.9M11.4M
Cash And Short Term Investments10.7M15.2M70.9M43.1M23.6M22.4M
Common Stock Total Equity21K29K46K69K79.4K83.3K
Common Stock Shares Outstanding452.5K656.4K1.8M1.9M2.0M1.6M
Liabilities And Stockholders Equity25.2M29.0M84.1M57.4M38.2M35.4M
Non Current Liabilities Total6.1M8.4M1.5M412K5.3M2.9M
Other Stockholder Equity55.1M74.5M151.7M154.0M157.7M83.7M
Total Liab9.7M11.3M5.1M5.2M12.1M6.5M
Total Current Assets13.5M17.2M72.5M45.6M26.3M24.0M
Accumulated Other Comprehensive Income31K65K41K12K(9K)(8.6K)
Short Term Debt103K118K96K116K100K174.4K
Common Stock21K29K46K69K33K33.6K
Other Liab1.4M5.8M8.2M1.4M1.6M3.1M
Property Plant And Equipment Net603K685K445K678K796K512.3K
Retained Earnings Total Equity(14.5M)(26.4M)(39.6M)(56.9M)(51.2M)(48.7M)
Capital Surpluse31.6M40.6M55.1M74.7M85.9M48.7M
Other Current Assets529K2.0M1.1M1.6M2.6M2.8M
Property Plant And Equipment Gross603K685K1.1M678K1.7M1.8M
Property Plant Equipment463K603K685K445K511.8K412.9K
Net Invested Capital15.6M17.8M79.0M52.2M26.1M34.9M
Net Working Capital9.9M14.3M68.9M40.8M19.5M25.7M
Net Receivables11K1K45K22K99K104.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.